DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages
Author: Dr Weng Chyn Chan, Dermatology Registrar, Waikato Hospital, Hamilton, New Zealand, 2004.
Rifampicin is an antibiotic used to treat serious bacterial infections. It may be prescribed by dermatologists for the treatment of:
Rifampicin is active against a variety of organisms including Staphylococcus aureus, coagulase negative staphylococcus, Mycobacterium tuberculosis, Mycobacterium leprae, Neisseria meningiditis and Brucella species.
In New Zealand rifampicin is available as:
Rifampicin is often prescribed with another antibiotic in order to prevent bacterial resistance, which can develop rapidly if it is used alone.
It should be taken on an empty stomach at least 30 minutes before a meal or 2 hours after a meal. Antacids should be given at least 1 hour after rifampicin.
Rifampicin is usually well-tolerated and rarely causes serious toxicity. The commonest side effects involve the skin and the gastrointestinal system.
Discoloured urine while on rifampicin
Tears, sweat and urine may become orange coloured by oral rifampicin. Contact lenses may be permanently stained. This effect is usually mild and self-limiting.
Rifampicin may cause loss of appetite, vomiting, abdominal pain and diarrhoea.
Hepatitis can be caused by rifampicin, particularly if rifampicin is given with isoniazid.
Serious haematological disorders have been reported in patients taking rifampicin, including:
Muscle weakness and myopathy are uncommon side effects of rifampicin.
Rifampicin is sometimes used intermittently (less than 2 to 3 doses per week) for the treatment of tuberculosis and leprosy. When rifampicin is used in this way, it may be associated with a ‘flu-like syndrome, shortness of breath, low blood pressure, acute renal failure and shock.
Rifampicin is a P-glycoprotein inducer and may increase the breakdown of other medications, making them less effective. The dosage of these drugs may need adjustment if they are taken together with rifampicin:
If you are not based in New Zealand, we suggest you refer to your national drug approval agency for further information about medicines (eg, the Australian Therapeutic Goods Administration and the US Food and Drug Administration) or a national or state-approved formulary (eg, the New Zealand Formulary and New Zealand Formulary for Children and the British National Formulary and British National Formulary for Children).
© 2022 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.